MSI-H
Clinical trials for MSI-H explained in plain language.
Never miss a new study
Get alerted when new MSI-H trials appear
Sign up with your email to follow new studies for MSI-H, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy combo may spare cancer patients from surgery
Disease control Recruiting nowThis study tests a combination of immunotherapy drugs (sintilimab, IBI310, lenvatinib) in people with non-spreading stomach or colon cancers that have a specific genetic feature (MSI-H/dMMR). The goal is to see if these drugs can make the cancer disappear or shrink enough so that…
Matched conditions: MSI-H
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated May 26, 2026 06:23 UTC
-
New drug duo aims to outperform standard care in Hard-to-Treat stomach cancer
Disease control Recruiting nowThis phase 3 study compares a new two-drug immunotherapy (botensilimab + balstilimab) against the current standard treatment (chemotherapy plus nivolumab) in people with advanced or metastatic stomach or esophageal cancer that has a specific genetic feature (MSI-H/dMMR). The goal…
Matched conditions: MSI-H
Phase: PHASE3 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated May 07, 2026 18:38 UTC